Abstract 373P
Background
Head and neck squamous cell carcinoma (HNSCC) is a common cancer worldwide with high mortality rates. Studies suggested the incidence of HNSCC will increase by approximately 30% by 2030. However, elderly patients with advanced HNSCC often face challenges in receiving sufficient treatment because of their lower tolerance to therapy. Exploring different approaches for HNSCC is crucial given the world's aging population.
Methods
The study between 2010 and 2021 involved patients with HNSCC located in the oral cavity, oropharynx, larynx, and hypopharynx. The research was focused on advanced-stage patients aged 70 or older. The data were collected from a cancer registry database at a referral institution. The Kaplan-Meier method was used to estimate overall survival (OS).
Results
The study included 1144 patients with HNSCC, of whom 207 (18.1%) were above 70 years old. Over 50% of the patients had advanced disease without metastasis, being stages III, IVA and IVB. The median OS for geriatric patients with advanced disease was 16.1 months. Patients who underwent curative-intent surgery, radiotherapy, or chemoradiotherapy had better survival rates than those who did not (log-rank test: all p < .01). Furthermore, patients with a higher body mass index (≥ 18.5) had improved OS (p = .03). No significant differences were observed in OS between geriatric patients who received systemic therapy or not. By the multivariate analysis, patients who underwent surgery demonstrated higher survival rates, while those with tumors located in the hypopharynx showed inferior outcomes. The median OS was 29.9 and 8.4 months, respectively (p < .01 and p = .01). Table: 373P
AJCC stage III and IV (M0) head and neck cancer (p < .01)
≥ 70-year-old patients | Number | 3-year survival rate |
Withoout curative surgery | 62 | 22.6% |
With curative surgery | 44 | 45.5% |
Conclusions
Geriatric patients with locally advanced HNSCC have a poor prognosis especially for hypopharyngeal cancer. The study suggests that curative surgery may be a beneficial treatment for these patients. However, further research is warranted to optimize treatments and improve outcomes and quality of life for this vulnerable group.
Clinical trial identification
Editorial acknowledgement
The authors would like to thank all colleagues who contributed to this study. The work was supported by the medical integration database of National Taiwan University Hospital and National Taiwan University Hospital Yunlin branch.
Legal entity responsible for the study
Y.T. Liu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract